Long-term safety – part 2/2
and herpes zoster than adalimumab and infliximab. Ustekinumab, launched more recently, is recommended in the British Association of Dermatologists biologic guidelines as second-line biologic therapy in patients with moderate-to-severe plaque psoriasis, due to a relative lack of long-term safety data at the time of publication. The short- and long-term risk of MACE for ustekinumab remains to be more precisely elucidated. However, recent data provided by Papp and colleagues suggests that long-term treatment with ustekinumab is not associated with an increased risk of MACE.14
Conclusions from the authors The above review of the AEs occurring in patients treated long-term (two to five years) with the biologics did not reveal any evidence of cumulative toxicity of either the anti-TNFa agents or ustekinumab. As expected, the anti-TNFs produced a slightly higher rate of serious infections and NMSC, but a larger number of patients and a longer observation time are needed to determine whether there is any increase in other known AEs listed in Tables 1 and 2. Biological agents seem to decrease the cumulative risk of MACE in psoriasis patients. The mean duration of drug exposure necessary to produce a single AE is in the range of 50 years and the risk of occurrence of any unpredicted AE is likely to be below 0.1%/year. Thus, the benefit/risk ratio for the biologics is very high, possibly even exceeding that of conventional systemic agents used in the therapy of psoriasis. Given that long-term safety is a critical determinant in the choice of treatment for chronic conditions, it is important that further studies be carried out for all of the biologics in order to establish their individual long-term safety profiles in patients with moderate-to-severe plaque psoriasis. It is expected that registries will contribute significantly to the safety dataset for biologics, especially with regard to real-world use, and a combination of data sources should provide the most comprehensive view of safety for biologics over the long term. l
References 1. Burmester GR et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68(12):1863–9.
2. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of
efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One 2012,7:e33486.
3. Langley RG et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010;162(6):1349–58.
4. Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol 2012;8(1):13–21.
5. Westlake SL et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology 2011;50(3):518–31.
6. Ljung L et al. Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012;64(1):42–52.
7. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010;39(5):327–46.
8. Saad AA, Symmons DPM, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35(5):883–90.
9. Dommasch ED et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011;64(6):1035–50.
10. Askling J, Dixon W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008;20(2):138–44.
11. Dixon WG et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007;56(9):2896–904.
12. Dixon WG et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54(8):2368–76.
13. Hoentjen F, Van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009;15(17):2067–73.
14. Papp KA et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168(4):844–54.
15. Rustin MHA. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol 2012;167:3–11.
16. Ryan C et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. J Amer Med Assoc
17. Reich K et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011;164(4):862–72.
18. Machin D et al. Sample size tables for clinical studies. Chapter 11. Post marketing surveillance. Wiley-Blackwell, Chichester, UK;2009:142–52. ISBN978-1-4051-4650-0.
19. Salliot C, Van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Annals Rheum Dis 2009;68(7):1100–4.
20. Girolomoni G et al. Safety of anti-TNFa agents in the treatment of psoriasis and psoriatic arthritis. Immunopharmacol Immunotoxicol 2012;34(4):548–60.
21. Mariette X, Gottenberg J-E, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2011;50(1):222–9.
22. Papp KA et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol 2012;11(10):1210–7.
23. Van Lümig PPM et al. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013;68(1):57–63.
24. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164(5):1091–6.
25. Ahlehoff O et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Int Med 2013;273(2):197– 204.
26. Reddy M et al. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters. J Dermatol 2010;37:413–25.
27. Singh JA et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. doi: 10.1002/14651858. CD008794.pub2.
28. Bongartz T et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006;295:2275–85
29. Lebwohl M et al. Long term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012;66:731–41.
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40